International Isotopes Inc INIS
We take great care to ensure that the data presented and summarized in this overview for INTERNATIONAL ISOTOPES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INIS
View allLatest Institutional Activity in INIS
Top Purchases
Top Sells
About INIS
International Isotopes Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services in the United States and internationally. It operates through five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. It offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items. The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources. The Radiochemical Products segment produces and distributes various isotopically pure radiochemicals and sodium iodide I-131 generic drug product for medical, industrial, and research applications. The Radiological Services segment provides flood source disposal and gemstones processing services. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. It sells its products directly to end users and distributors. International Isotopes Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.
Insider Transactions at INIS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 22
2024
|
W Matthew Cox Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
60,000
+6.26%
|
$0
$0.03 P/Share
|
Nov 20
2024
|
Shahe Bagerdjian Pres. & CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+1.05%
|
$0
$0.04 P/Share
|
Nov 20
2024
|
W Matthew Cox Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+3.46%
|
$0
$0.04 P/Share
|
Nov 14
2024
|
Christopher G Grosso Director |
BUY
Open market or private purchase
|
Indirect |
401,117
+28.1%
|
$0
$0.03 P/Share
|
Sep 18
2024
|
Christopher G Grosso Director |
BUY
Open market or private purchase
|
Indirect |
300,000
+32.43%
|
$0
$0.03 P/Share
|
Sep 18
2024
|
Christopher G Grosso Director |
BUY
Open market or private purchase
|
Direct |
500,000
+1.28%
|
$0
$0.03 P/Share
|
Sep 13
2024
|
Shahe Bagerdjian Pres. & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+3.63%
|
-
|
Jun 14
2024
|
W Matthew Cox Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
239,669
+22.88%
|
$0
$0.04 P/Share
|
Jun 14
2024
|
Shahe Bagerdjian Pres. & CEO |
BUY
Open market or private purchase
|
Direct |
250,000
+2.72%
|
$0
$0.04 P/Share
|
Apr 17
2024
|
Shahe Bagerdjian Pres. & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
531,750
-5.76%
|
$0
$0.04 P/Share
|
Dec 14
2023
|
W Matthew Cox Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
250,000
+31.69%
|
$0
$0.02 P/Share
|
Dec 14
2023
|
Shahe Bagerdjian Pres. & CEO |
BUY
Open market or private purchase
|
Direct |
1,000,000
+9.78%
|
$0
$0.02 P/Share
|
Sep 05
2023
|
Shahe Bagerdjian Pres. & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
778,972
-8.65%
|
$0
$0.06 P/Share
|
Sep 05
2023
|
Shahe Bagerdjian Pres. & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,500,000
+21.73%
|
-
|
Aug 25
2023
|
Shahe Bagerdjian Pres. & CEO |
BUY
Open market or private purchase
|
Direct |
3,950
+0.06%
|
$0
$0.05 P/Share
|
May 10
2023
|
Shahe Bagerdjian Pres. & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,500,000
+50.0%
|
-
|
Mar 03
2023
|
Robert Atcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
750,000
+50.0%
|
-
|
Feb 28
2023
|
Steve Laflin Pres. & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
216,440
-2.22%
|
$0
$0.04 P/Share
|
Feb 28
2023
|
Steve Laflin Pres. & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
560,000
+5.43%
|
-
|
Nov 15
2022
|
Christopher G Grosso Director |
BUY
Open market or private purchase
|
Indirect |
1,410,000
+11.44%
|
$0
$0.03 P/Share
|
Last 12 Months Summary
Open market or private purchase | 1.88M shares |
---|---|
Grant, award, or other acquisition | 350K shares |
Payment of exercise price or tax liability | 532K shares |
---|